Gufic Biosciences Limited

NSE GUFICBIO.NS

Gufic Biosciences Limited Price to Earnings Ratio (P/E) on January 14, 2025: 51.63

Gufic Biosciences Limited Price to Earnings Ratio (P/E) is 51.63 on January 14, 2025, a 20.21% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Gufic Biosciences Limited 52-week high Price to Earnings Ratio (P/E) is 55.83 on November 08, 2024, which is 8.15% above the current Price to Earnings Ratio (P/E).
Gufic Biosciences Limited 52-week low Price to Earnings Ratio (P/E) is 33.91 on April 01, 2024, which is -34.32% below the current Price to Earnings Ratio (P/E).
Gufic Biosciences Limited average Price to Earnings Ratio (P/E) for the last 52 weeks is 43.20.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NSE: GUFICBIO.NS

Gufic Biosciences Limited

CEO	Mr. Pranav Jayesh Choksi
IPO Date	Oct. 19, 2004
Location	India
Headquarters	SM House
Employees	1,491
Sector	Health Care
Industries Pharmaceuticals

Description

Gufic Biosciences Limited engages in manufacture and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac, infertility, antiviral, and proton-pump inhibitor segments. In addition, it offers spark, criti care, and ferticare pharmaceutical products; and herbal and personal care products. The company supplies its products to hospital chains and medical facilities. It also exports its products to more than 20 countries. The company was founded in 1970 and is based in Mumbai, India.

Key trends

Past 5 years